Drug Profile
MSB 0221
Alternative Names: MSB-01; MSB-0221; TMT lotionLatest Information Update: 24 Mar 2021
Price :
$50
*
At a glance
- Originator MatriSys Bio
- Developer National Institute of Allergy and Infectious Diseases
- Class Antibacterials; Bacteria; Skin disorder therapies
- Mechanism of Action Microbiome modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Atopic dermatitis
Highest Development Phases
- Phase I/II Atopic dermatitis
Most Recent Events
- 24 Mar 2021 Phase-I/II development is ongoing for Atopic dermatitis in USA (MatriSys Bio pipeline, March 2021)
- 22 Feb 2021 Efficacy data from a phase I/II trial in Atopic dermatitis released by MatriSys Bio
- 04 Jan 2021 MatriSys Bioscience plans a phase II trial in Atopic dermatitis in 2023 (Topical)